Fly News Breaks for March 6, 2015
CMRX
Mar 6, 2015 | 10:51 EDT
Piper Jaffray said Chimerix continues to advance brincidofovir on multiple fronts despite the SUPPRESS trial results being delayed to 2016. The firm increased its price target on the stock to $44 from $41 and reiterated its Overweight rating on the shares, which are down 6.6% to $38.10 in morning trading following the company's quarterly report.
News For CMRX From the Last 2 Days
There are no results for your query CMRX